Via Microinjection Of A Nucleus Into An Embryo, Egg Cell, Or Embryonic Cell Patents (Class 800/24)
-
Publication number: 20080120733Abstract: The invention relates to a method for the production of a eukaryotic cell selectable by inactivation or reduction of an endogenous gene function, comprising the steps of (a) introduction of one or more vectors into the cell and (b) expression of a siRNA and preferably shRNA coded by the one or more vectors, directed against an endogenous selectable gene and inactivating same, said siRNA or shRNA being the transcription product of an RNAi selection cassette, the selection cassette comprising a section of at least 19 nucleotides of the transcribed region of the gene, said selection being operatively linked to a promoter and a transcription termination signal.Type: ApplicationFiled: June 16, 2005Publication date: May 22, 2008Applicant: GBF-GESELLSCHAFT FUR BIOTECHNOLOGISCHE FORSCHUNGInventors: Martin Hafner, Karina Nawrath, Werner Muller
-
Patent number: 7371922Abstract: Provided is a method for the production of transgenic animals, especially pigs, by the use of nuclear transfer from genetically modified or other embryonic stem cells to either enucleated oocytes which were matured in vivo or in vitro and activated or to enucleated zygotes.Type: GrantFiled: July 31, 2003Date of Patent: May 13, 2008Assignee: The Board of Trustees of the University of IllinoisInventors: Matthew B. Wheeler, Brett R. White
-
Patent number: 7361804Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: August 29, 2000Date of Patent: April 22, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7358416Abstract: Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous RcRn disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a substantially shorter half-life, as compared to the half-life of exogenously administered IgG1 in a wild-type mouse. The transgenic knockout mouse with a homozygous RcRn disruption is also unable to absorb maternal IgG in the prenatal or neonatal stage of development. Also disclosed is a transgenic knockout mouse comprising a homozygous FcRn disruption and a human FcRn transgene. The transgenic addition of human FcRn results in a substantial increase in the half-life of exogenously administered human IgG1. Methods of using the transgenic knockout mouse, and cells derived from them, are also disclosed.Type: GrantFiled: September 27, 2005Date of Patent: April 15, 2008Assignee: The Jackson LaboratoryInventor: Derry Roopenian
-
Patent number: 7355094Abstract: A method of reconstituting an animal embryo involves transferring the nucleus from a quiescent donor cell into a suitable recipient cell. The donor cell is quiescent, in that it is caused to exit from the growth and division cycle at G1 and to arrest in the G0 state. Nuclear transfer may take place by cell fusion. The reconstituted embryo may then give rise to one or more animals. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: October 6, 2006Date of Patent: April 8, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7351876Abstract: This invention relates to a method for breeding animals via cloning and the animals obtainable by the method, in particular a method for reproducing animal embryos via efficient nuclear transfer with primordial gametes.Type: GrantFiled: September 12, 2002Date of Patent: April 1, 2008Assignee: Agrobiogen GmbH BiotechnologieInventors: Gottfried Brem, Gabriela Durcova-Hills, Sigrid Müller, Wolfgang Schernthaner, Hendrik Wenigerkind, Eckhard Wolf, Valeri Zakhartchenko
-
Patent number: 7335811Abstract: Methods for collecting cells in M phase or G1 phase, by which the percentage of M phase or G1 phase cells is higher than that attained by the conventional methods are disclosed.Type: GrantFiled: July 17, 2002Date of Patent: February 26, 2008Assignee: The Japanese Research Association for Animal Embryo Transfer Technology c/o Livestock Improvement Association of JapanInventors: Manami Urakawa, Yoshito Aoyagi
-
Publication number: 20080044392Abstract: The present invention relates to isolated stem cell-like cells and a method of isolation. The invention also relates to a media composition for producing primary cell cultures comprising predominantly tissue-specific progenitor cells or stem cell-like cells. In particular, the present invention relates to an isolated mesenchymal connective tissue-derived stem cell.Type: ApplicationFiled: October 15, 2004Publication date: February 21, 2008Applicant: INNOVATIVE DAIRY PRODUCTS PTY LTD AS TRUSTEE FOR THE PARTICIPANTS OF THE COOOPERATIVE RESEARCH CTRInventors: Wilfried A Kues, Heiner Niemann
-
Patent number: 7332648Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: November 21, 2001Date of Patent: February 19, 2008Assignee: Roslin InstituteInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7332647Abstract: The disclosure provided herein teaches that fertile transgenic fish can be generated by nuclear transfer using cultured cells as embryonic fibroblasts.Type: GrantFiled: June 11, 2003Date of Patent: February 19, 2008Assignee: The Regents of the University of CaliforniaInventor: Shuo Lin
-
Patent number: 7329796Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: August 3, 2004Date of Patent: February 12, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7326825Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: October 6, 2006Date of Patent: February 5, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7326824Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: July 9, 2002Date of Patent: February 5, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7323620Abstract: A method for activating an equine oocyte comprising exposing oocyte to a medium containing a concentration of calcium of at least about 4 mM. Preferably the oocyte is exposed to this concentration of calcium during activation.Type: GrantFiled: April 9, 2003Date of Patent: January 29, 2008Assignee: Idaho Research Foundation, Inc.Inventors: Gordon L. Woods, Dirk K. Vanderwall
-
Patent number: 7321075Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: September 5, 2002Date of Patent: January 22, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7321076Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: August 10, 2004Date of Patent: January 22, 2008Assignee: Roslin InstituteInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7307198Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: November 21, 2001Date of Patent: December 11, 2007Assignee: Roslin InstituteInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7304204Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: November 21, 2001Date of Patent: December 4, 2007Assignee: Roslin InstituteInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7297837Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation.Type: GrantFiled: April 26, 2000Date of Patent: November 20, 2007Assignee: The John Hopkins UniversityInventors: Nicholas Nicolaides, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 7294508Abstract: A method for isolating an inner cell mass comprising the steps of immobilizing a blastocyst stage embryo having a zona pellucida, trophectoderm, and inner cell mass, creating an aperture in the blastocyst stage embryo by laser ablation, and removing the inner cell mass from the blastocyst stage embryo through the aperture. The aperture is through the zona pellucida and the trophectoderm. The laser ablation is acheived using a non-contact diode laser. The inner cell mass removed from the blastocyst stage embryo is used to establish human Embryonic Stem Cell lines.Type: GrantFiled: August 23, 2002Date of Patent: November 13, 2007Assignee: Reliance Life Sciences Pvt. Ltd.Inventors: Firuza Rajesh Parikh, Satish Mahadoerao Totey, Shailaja Anupam Saxena
-
Patent number: 7291764Abstract: An improved method of nuclear transfer involving the transplantation of donor differentiated pig cell nuclei into enucleated pig oocytes is provided. The resultant nuclear transfer units are useful for multiplication of genotypes and transgenic genotypes by the production of fetuses and offspring. Production of genetically engineered or transgenic pig embryos, fetuses and offspring is facilitated by the present method since the differentiated cell source of the donor nuclei can be genetically modified and clonally propagated.Type: GrantFiled: September 13, 1999Date of Patent: November 6, 2007Assignee: University of Massachusetts, a Public Institution of Higher Education of the Commonwealth of Massachusetts, as Represented by its Amherst Campus, Office of Vice Chancellor for Research at AmherstInventors: Steven L. Stice, Jose Cibelli, James Robl, Paul Golueke
-
Patent number: 7265262Abstract: This disclosure provides a system for creating cloned cells and embryos that are genetically modified. Cells are treated to increase expression of telomerase and potentially extend replicative capacity. One or more genetic modifications is made to inactivate a gene or confer desirable features, growing and selecting the cells as needed. The modified nucleus can then be transferred to a suitable recipient cell, which can then be used to grow an embryo with the conferred attributes. This technology makes it possible to create embryos, animals and embryonic cell lines with multiple genetic modifications, including homozygously inactivated genes and gene substitutions.Type: GrantFiled: March 21, 2002Date of Patent: September 4, 2007Assignee: Roslin Institute (Edinburgh)Inventors: A. John Clark, Wei Cui, Chris Denning, Debbiao Zhao
-
Patent number: 7259291Abstract: A method of enucleating an egg by exposing the egg to gamma irradiation. The dose of gamma irradiation used is sufficiently high to halt development of the egg or embryo derived therefrom directed by the nucleus of the irradiated egg, but sufficiently low to enable development of the egg or embryo directed by a nucleus transferred into the enucleated egg.Type: GrantFiled: December 13, 2002Date of Patent: August 21, 2007Assignee: Viragen IncorporatedInventors: Helen Sang, Adrian Sherman
-
Patent number: 7253334Abstract: The invention provides methods for cloning mammals that allow the donor chromosomes or donor cells to be reprogrammed prior to insertion into an enucleated oocyte. The invention also features methods of inserting chromosomes or nuclei into recipient cells.Type: GrantFiled: December 21, 2001Date of Patent: August 7, 2007Assignee: Aurox, LLCInventors: Philippe Collas, James M. Robl, Eddie Sullivan, Poothappillai Kasinathan
-
Patent number: 7235709Abstract: Transgenic non-human mammals over-expressing MHCI in skeletal muscle are provided herein, as are methods of using these transgenic non-human mammals for screening candidate compounds for treating type 2 diabetes, and methods for altering the ratio of MHCI to MHCII in a subject.Type: GrantFiled: October 29, 2004Date of Patent: June 26, 2007Assignee: Mayo Foundation for Medical Education and ResearchInventors: K. Sreekumaran Nair, Laura J. Greenlund
-
Patent number: 7232938Abstract: A method of reconstituting an animal embryo involves transferring the nucleus from a quiescent donor cell into a suitable recipient cell. The donor cell is quiescent, in that it is caused to exit from the growth and division cycle at G1 and to arrest in the G0 state. Nuclear transfer may take place by cell fusion. The reconstituted embryo may then give rise to one or more animals. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: August 11, 2004Date of Patent: June 19, 2007Assignee: Roslin InstituteInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7202395Abstract: A method of assessing the viability of a cell comprises incubating the cell in a culture medium. The culture medium includes a plurality of amino acids and the change in concentration in the medium of at least one amino acid is determined.Type: GrantFiled: January 19, 2001Date of Patent: April 10, 2007Assignee: The University of YorkInventors: Henry John Leese, Francesca Dawn Houghton, Peter Gordon Humpherson
-
Patent number: 7196243Abstract: The present invention is directed toward a transgenic non-human animal and uses thereof, wherein each of the cells of the animal contain a transgene comprising a nucleic acid sequence encoding CD200.Type: GrantFiled: April 3, 2003Date of Patent: March 27, 2007Assignee: Trillium Therapeutics Inc.Inventor: Reginald M. Gorczynski
-
Patent number: 7161058Abstract: The present invention relates to a non-human transgenic animal, particularly a knock in mouse, whose genome comprises a heterologous, chimeric CTLA4 gene. The chimeric CTLA4 gene comprises exon 2 of the human CTLA4 gene, exon 1 and exon 4 of the non-human animal, and exon 3 of the CTLA4 gene of the non-human animal, or preferably, exon 3 of the human CTLA4 gene. The invention also relates to methods by which the transgenic mice are used to screen for monoclonal antibodies or other molecules that enhance immunity to tumors and infectious agents by interacting with the human CTLA4 receptor. The transgenic mice of the present invention are also useful for screening for monoclonal antibodies or other molecules that inhibit autoimmunity and transplant rejection.Type: GrantFiled: February 7, 2005Date of Patent: January 9, 2007Assignee: The Ohio State University Research FoundationInventors: Yang Liu, Pan Zheng, Ping Lu, Bedrich Mosinger, Ken May
-
Patent number: 7126039Abstract: This disclosure provides a system for generating animal tissue with carbohydrate antigens that are compatible for transplantation into human patients. The tissue is inactivated homozygously for expression of ?(1,3)galactosyltransferase, and comprises a transgene for ?(1,2)fucosyltransferase. As a result, cell-surface N-acetyl lactosamine is not converted to the Gal?(1,3)Gal xenoantigen. Instead, it is converted to Fuc?(1,2)Gal, which is H substance, a self-antigen in humans. The tissue may also contain A or B-transferase, which will cause H substance to be converted into other ABO blood group antigens for compatibility with patients of the same blood type. This invention improves transplant compatibility of the xenograft tissue by lessening the risk of reactions resulting from xenoantigen and unconverted N-acetyl lactosamine acceptor determinants.Type: GrantFiled: March 21, 2002Date of Patent: October 24, 2006Assignee: Geron CorporationInventors: Chris Denning, A. John Clark, J. Michael Schiff
-
Patent number: 7115795Abstract: The invention provides a transgenic animal having within its genome a transgene construct for gastrointestinal tract specific expression of a protein. In a preferred embodiment, the protein is a phytase or a homologue thereof. Such proteins may be heterologous and may be specifically expressed in the salivary gland of the animal by operably linking the nucleic acid sequence encoding the protein with regulatory sequence including a salivary gland protein promoter/enhancer. Also provided are methods of expressing and producing proteins using such nucleic acid constructs. Further, antibodies specific to such proteins and immunological diagnostic kits are also provided.Type: GrantFiled: April 20, 2000Date of Patent: October 3, 2006Assignee: University of GuelphInventors: Cecil W. Forsberg, Serguei Golovan, John P. Phillips
-
Patent number: 7098376Abstract: The present invention makes available powerful tools for the study of cancer, based on a novel expression construct for a constitutively active hydrocarbon receptor CA-AhR. The invention further comprises transgenic non-human animals, preferably mammals, expressing CA-AhR in one or more tissues thereof. An animal model based on the transgenic non-human animals forms the basis for novel methods e.g. for the study of cancer; for the screening of compounds, such as drug candidates; for the investigation of the molecular mechanisms of cancer, in particular stomach cancer; for the investigation of the mechanisms of highly differentiated adenocarcinoma etc. Likewise, in vitro models based on transformed cells or cell lines, functionally incorporating the inventive construct are disclosed.Type: GrantFiled: October 25, 2001Date of Patent: August 29, 2006Assignee: InDex Pharmaceuticals ABInventors: Lorenz Poellinger, Jaqueline McGuire, Annika Hanberg Wiklund, Patrik Andersson
-
Patent number: 7071372Abstract: An improved method of nuclear transfer employing long-term cultured somatic cells as the donor cells and enucleated oocytes as the recipient cells to produce dividing cybrids. Such cybrids are useful for developing viable animals clones when nurtured in a suitable host environment.Type: GrantFiled: January 4, 2001Date of Patent: July 4, 2006Assignees: University of Connecticut, The Governor of Kagoshima PrefectureInventors: Xiangzhong Yang, Chikara Kubota
-
Patent number: 7071373Abstract: Transgenic ungulates and compositions and methods for making and using same, are provided. Central to the invention are porcine, bovine, ovine and caprine embryonic stem cell lines and methods for establishing them. Cells of such lines are transformed with exogenous genetic material of interest and then used to provide chimeric ungulates confirmed by genetic markers which have germ cells comprising the exogenous genetic material. The chimeric ungulates are bred to provide transgenic ungulates. The transgenic animals of the invention may show improved qualities and can be used to provide human proteins or peptide hormones or can be used as xenograft donors.Type: GrantFiled: March 24, 1995Date of Patent: July 4, 2006Assignee: The Board of Trustees of the University of IllinoisInventor: Matthew B. Wheeler
-
Patent number: 7064245Abstract: This invention relates to the generation of animals by the transfer of somatic cells which have been denatured preferably by heating, into enucleated metaphase II oocytes. This invention may be useful for the cloning of mammals including but not being limited to genetically selected and/or transgenic animals.Type: GrantFiled: June 4, 1999Date of Patent: June 20, 2006Assignee: Istituto Zootecnico E Caseario per La SardegnaInventors: Pasqualino Loi, Pietro Cappai
-
Patent number: 7053264Abstract: Methods and compositions for dedifferentiating nuclei from somatic cells are provided. Such methods and compositions are useful for facilitating processes such as, for example, cloning and immortalization of cells.Type: GrantFiled: September 28, 2001Date of Patent: May 30, 2006Assignee: Sangamo Biosciences, Inc.Inventors: Elizabeth Wolffe, legal representative, Alan P. Wolffe, deceased
-
Patent number: 7049480Abstract: The invention includes methods of enucleating avian eggs comprising visualizing internal structure of an avian egg utilizing TPLSM and ablating the nucleus of the egg by near-infrared light.Type: GrantFiled: September 1, 2000Date of Patent: May 23, 2006Assignee: AviGenics, Inc.Inventors: Leandro Christmann, Scott L. Pratt, Jeffrey C. Rapp
-
Patent number: 7041870Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: GrantFiled: November 30, 2001Date of Patent: May 9, 2006Assignees: Medarex, Inc., Kirin Brewery Company LimitedInventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
-
Patent number: 7034200Abstract: Non-human transgenic animals overexpressing PDGF-C and cells thereof have been created. The transgenic animals contain a nucleotide sequence that encodes for platelet derived growth factor C (PDGF-C) or an analog thereof, or a functional fragment of PDGF-C or analog thereof. These animals are useful for studying disease states characterized by overexpression of PDGF-C, as well as useful for evaluating therapies intended to treat such diseases.Type: GrantFiled: March 28, 2001Date of Patent: April 25, 2006Assignee: Ludwig Institute for Cancer ResearchInventors: Ulf Eriksson, Xuri Li, Annica Ponten, Karin Aase, Hong Li
-
Patent number: 7030292Abstract: A method of producing a homogenous population of homozygous stem (HS) cells pre-selected for immunotype and/or genotype from donor cells is described herein. The invention relates to methods of using immunohistocompatible HS cells for diagnosis, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, traumatic injuries and cancer. The invention further relates to methods for using histocompatible HS stem cells pre-selected for a non-disease genotype for prophylactic and therapeutic intervention including, but not limited to, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, and cancer.Type: GrantFiled: January 2, 2002Date of Patent: April 18, 2006Assignee: Stemron, Inc.Inventors: Wen Liang Yan, Steve Chien-Wen Huang, Minh-Thanh Nguyen, Huan (Helen) Lin, Jingqi Lei, Ruchi Khanna
-
Patent number: 6906238Abstract: The present invention provides methods of producing a cloned non-human mammalian nuclear transfer (NT) embryo and methods for producing a cloned non-human mammal. Embodiments of the methods include introducing donor genetic material into a metaphase I oocyte; introducing donor genetic material into a non-enucleated oocyte; introducing donor genetic material obtained from a donor cell that is at metaphase into an oocyte; introducing donor genetic material into an oocyte, and naturally activating the oocyte or the NT embryo; and introducing donor genetic material obtained from a donor cell that is at late G1 phase into an oocyte.Type: GrantFiled: March 15, 2001Date of Patent: June 14, 2005Assignee: University of Georgia Research Foundation, Inc.Inventor: Steven Stice
-
Patent number: 6875904Abstract: The present invention relates to a non-human transgenic animal, particularly a knock in mouse, whose genome comprises a heterologous, chimeric CTLA4 gene. The chimeric CTLA4 gene comprises exon 2 of the human CTLA4 gene, exon 1 and exon 4 of the non-human animal, and exon 3 of the CTLA4 gene of the non-human animal, or preferably, exon 3 of the human CTLA4 gene. The invention also relates to methods by which the transgenic mice are used to screen for monoclonal antibodies or other molecules that enhance immunity to tumors and infectious agents by interacting with the human CTLA4 receptor. The transgenic mice of the present invention are also useful for screening for monoclonal antibodies or other molecules that inhibit autoimmunity and transplant rejection.Type: GrantFiled: September 20, 2001Date of Patent: April 5, 2005Assignee: The Ohio State University Research FoundationInventors: Yang Liu, Pan Zheng, Ping Lu, Bedrich Mosinger, Ken May
-
Patent number: 6808704Abstract: This invention relates to methods for making immune compatible tissues and cells for the purpose of transplantation and tissue engineering, using the techniques of nuclear transfer and cloning. Also encompassed are methods for determining the effect on immune compatibility of expressed transgenes and other genetic manipulations of the engineered cells and tissues.Type: GrantFiled: September 6, 2000Date of Patent: October 26, 2004Assignee: Advance Cell Technology, Inc.Inventors: Robert Lanza, Michael D. West, Jose Cibelli
-
Publication number: 20040187173Abstract: The present invention provides methods of producing a clone non-human mammalian nuclear transfer (NT) embryo and methods for producing a cloned non-human mammal. Embodiments of the methods include introducing doner genetic material into a metaphase I oocyte; introducing donor genetic material into a non-enucleated oocyte; introducing donor genetic material obtained from a donor cell that is a metaphase into an oocyte; introducing donor genetic material into an oocyte, and naturally activating the oocyte or the NT embryo; and introducing donor genetic material obtained from a donor cell that is at late G1 phase into anoocyte.Type: ApplicationFiled: March 25, 2004Publication date: September 23, 2004Inventor: Steven Stice
-
Patent number: 6781030Abstract: The present invention pertains to methods for cloning animals. In particular, the invention includes methods of cloning an animal by combining a genome from an activated donor cell with an activated enucleated oocyte to thereby obtain a nuclear transfer embryo, and impregnating an animal with the nuclear transfer embryo in conditions suitable for gestation of a cloned animal. The invention further relates to methods of chemically enucleating an oocyte having a meiotic spindle apparatus by exposing the oocyte with a compound that destabilizes the meiotic spindle apparatus.Type: GrantFiled: November 2, 1999Date of Patent: August 24, 2004Assignee: Trustee of Tufts College, Ballou HallInventors: Alexander Baguisi, Eric W. Overstrom
-
Patent number: 6753457Abstract: The present invention concerns products and methods particularly useful for activating and analyzing non-dividing cell nuclei. The featured products include activating egg extracts, cytostatic factor (CSF) extracts, kits containing these extracts, and a microchamber microscope slide useful in analyzing nucleus activation.Type: GrantFiled: January 6, 1999Date of Patent: June 22, 2004Assignee: TranxenogenInventor: Lawrence J. Wangh
-
Patent number: 6700037Abstract: The present invention relates to materials and methods for cloning porcine animals. The invention relates in part to totipotent cells useful for cloning porcine animals, porcine embryos produced from such cells by employing nuclear transfer techniques, and porcine animals that arise from such cells and embryos.Type: GrantFiled: December 28, 2000Date of Patent: March 2, 2004Assignee: Infigen, Inc.Inventors: Philip Damiani, Jeffrey M. Betthauser, Erik J. Forsberg, Michael D. Bishop
-
Patent number: 6635802Abstract: Provided are methods and compositions for increasing the efficiency of nuclear transfer using apoptosis inhibitors, and for the production of transgenic and non-transgenic mammals from cultured cells or cell lines. Methods for cloning mammals, and for producing transgenic and chimeric mammalian tissues and mammals, and chimeric cell lines are also provided.Type: GrantFiled: January 10, 2001Date of Patent: October 21, 2003Assignee: The Texas A&M University SystemInventors: Jorge A. Piedrahita, Chang-Kyu Lee, Regina Weaks, Fuller Bazer
-
Patent number: 6603059Abstract: The present invention relates to cloning technologies. The invention relates in part to immortalized and totipotent cells useful for cloning animals, the embryos produced from these cells using nuclear transfer techniques, animals that arise from these cells and embryos, and materials, methods, and processes for establishing such cells, embryos, and animals.Type: GrantFiled: October 16, 2000Date of Patent: August 5, 2003Assignee: Infigen, Inc.Inventors: Nikolai S. Strelchenko, Jeffrey M. Betthauser, Gail L. Jurgella, Marvin M. Pace, Michael D. Bishop
-
Patent number: 6600087Abstract: This invention relates to a process for breeding animals through cloning as well as animals obtainable with the process, in particular to a process for the reproduction of animal embryos via an efficient nucleus transfer with foetal fibroblasts.Type: GrantFiled: October 12, 1999Date of Patent: July 29, 2003Assignee: Agrobiogen GmbHInventors: Gottfried Brem, Gabriela Durcova-Hills, Sigrid Müller, Wolfgang Schernthaner, Hendrik Wenigerkind, Eckard Wolf, Valeri Zakhartchenko